News | News By Subject | News by Disease News By Date | Search News

Shingles News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
GlaxoSmithKline (GSK)'s Shingles Vaccine Demonstrates 90% Efficacy in Pivotal Phase III Study     10/27/2015
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine Hits Goal In Late-Stage Study     12/19/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Merck & Co., Inc. (MRK)'s Shingles Vaccine Not Reaching Enough U.S. Adults     9/12/2013
Depomed, Inc. (DEPO) Sues FDA to Get Sales Exclusivity for Shingles Pain Drug     9/26/2012
Merck & Co., Inc. (MRK) Tries Promoting Shingles Vaccine Again     4/16/2012
GlaxoSmithKline (GSK) Wants OK to Market Horizant for Shingles Pain     8/10/2011
Johnson & Johnson (JNJ) Warns Doctors of Doxil Cancer-Drug Shortage     7/22/2011
FDA Expands Indication for ZOSTAVAX(R), Merck & Co., Inc. (MRK)’s Shingles Vaccine, to Include Adults Ages 50 to 59     3/25/2011
Depomed, Inc. (DEPO)'s Shingles Drug Gets OK from FDA     1/31/2011
Merck & Co., Inc. (MRK)'s Shingles Vaccine Holds Up in Clinic, but Underused     1/12/2011
NeurogesX, Inc. (NGSX) Says Shingles-Pain Patch Available     4/6/2010
FDA Approves ZOSTAVAX(R), Merck & Co., Inc. (MRK)'s New Vaccine For Prevention Of Shingles In Adults Age 60 And Older     5/26/2006
FDA Delays Decision On Merck & Co., Inc. (MRK) Shingles Vaccine     2/24/2006

News from Around the Web
Childhood Asthma May Increase Risks Of Shingles, Mayo Clinic Study     12/29/2015
A Vaccine Mystery Hits Older Americans, Centers for Disease Control and Prevention (CDC) Reveals     9/5/2014
Stroke Risk Higher After Shingles, But Antiviral Drugs May Provide Protection, London School Of Hygiene & Tropical Medicine Study     4/4/2014
American College of Rheumatology: Proof Builds for Shingles Risk with Anti-TNFs     11/9/2010
Merck & Co., Inc. (MRK) Zostava Shingles Vaccine Effective in Adults in Their 50s     10/21/2010
Shingles Vaccine Safe But Not Widely Used, Marshfield Clinic Research Foundation Study     5/4/2010
Chickenpox Vaccine May Protect Kids From Shingles, Kaiser Permanente Study     12/4/2009
Shingles Raises Stroke Risk By 30 Percent, Taipei Medical University Hospital Study     10/9/2009
Prescription Painkiller Relieves Shingles Pain, University of Rochester Study     4/6/2009
Rheumatoid Arthritis Drugs Raise Shingles Risk, JAMA Report     2/18/2009
Centers for Disease Control and Prevention (CDC) Recommends Shingles Vaccine For Age 60 And Up     5/16/2008
Tai Chi Boosts Immunity to Shingles Virus in Older Adults, National Institutes of Health (NIH) Sponsored Study Reports     4/9/2007
Gov't Panel Recommends Shingles Vaccine     10/26/2006
Experts: Price May Block Shingles Vaccine     9/26/2006
Experimental Vaccine Helps Reduce Shingles     6/2/2005

Press Releases
Sorrento (SRNE) Subsidiary, Scilex Announces Key Endpoints Met In Pivotal Bioequivalence Clinical Study For Its Lead Product, ZTlido     12/5/2016
National Multisite Study Led By NYU Langone Medical Center Seeks New & Innovative Ways To Treat Shingles Of The Eye     11/17/2016
NanoViricides, Inc. (NNVC.PK) Signs Agreement With SUNY Upstate Medical Center For Testing Of Its Drug Candidates For The Treatment Of Shingles     10/31/2016
GlaxoSmithKline (GSK) Seeks FDA Green Light for Its Potential $1 Billion Shingles Vaccine     10/24/2016
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine 90% Effective in People Over Age 70     9/15/2016
ContraVir Expands Patient Enrollment Criteria For Ongoing Phase III Clinical Study Of FV-100 For Treating Shingles     6/16/2016
BIO2016: ContraVir To Present At 2016 Biotechnology Innovation Organization International Convention     6/2/2016
ContraVir To Expand Hepatitis B Portfolio Through Strategic Merger Agreement With Ciclofilin Pharmaceuticals     5/31/2016
ContraVir Invited To Present CMX157 Data At CHI's Eleventh Annual Drug Discovery Chemistry Conference     4/14/2016
ContraVir Reports Positive Results Confirming The Safety Of Its Shingles Candidate FV-100 In A Drug-Drug Interaction Study     3/3/2016
ContraVir To Present At Two Upcoming Investor Conferences     2/4/2016
ContraVir To Present At Biotech Showcase 2016     1/5/2016
ContraVir Reports Key CMX157 Data At HEP DART 2015 Demonstrating Enhanced In Vitro Safety Profile Compared To Viread     12/8/2015
ContraVir Strengthens Board Of Directors With Addition Of Industry Veteran Arnold Lippa, Ph.D.     12/3/2015
ContraVir To Present New CMX157 Data At HEP DART 2015     12/1/2015

//-->